Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

SABCS 2015

8 - 12 Dec 2015
TBC, San Antonio, United States of America
Biomarker driven clinical trials
Dr Oleg Gluz - West German Study Group Monchengladbach, Germany
Biomarker driven clinical trials ( Dr Oleg Gluz - West German Study Group Monchengladbach, Germany )
20 Dec 2016
Buparlisib helps overcome endocrine resistance in metastatic breast cancer: BELL...
Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes, ...
Buparlisib helps overcome endocrine resistance in metastatic breast cancer: BELLE-2 trial results ( Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes, France. )
17 Dec 2015
Survival outcomes from the CALGB 40603 study in triple-negative breast cancer
Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA
Survival outcomes from the CALGB 40603 study in triple-negative breast cancer ( Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA )
17 Dec 2015
TH3RESA: T-DM1 improves overall survival in previously treated advanced cancer p...
Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium
TH3RESA: T-DM1 improves overall survival in previously treated advanced cancer patients ( Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium )
17 Dec 2015
Molecular evolution of breast cancer during neoadjuvant chemotherapy
Prof Anne-Lise Børresen-Dale - Oslo University Hospital, Oslo, Norway
Molecular evolution of breast cancer during neoadjuvant chemotherapy ( Prof Anne-Lise Børresen-Dale - Oslo University Hospital, Oslo, Norway )
17 Dec 2015
NSABP FB-7: Neoadjuvant therapy with neratinib plus trastuzumab in locally advan...
Dr Samuel Jacobs - NSABP Foundation, Pittsburgh, USA
NSABP FB-7: Neoadjuvant therapy with neratinib plus trastuzumab in locally advanced HER2-positive breast cancer ( Dr Samuel Jacobs - NSABP Foundation, Pittsburgh, USA )
17 Dec 2015
HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in...
Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada
HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer ( Dr John Bartlett -  Ontario Institute for Cancer Research, Toronto, Canada )
17 Dec 2015
Trastuzumab emtansine improves overall survival versus treatment of physician's ...
Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium
Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated  HER2-positive metastatic breast cance ( Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium )
17 Dec 2015
Homologous recombination deficiency predicts neo-adjuvant chemotherapy response ...
Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX
Homologous recombination deficiency predicts neo-adjuvant chemotherapy response in triple-negative breast cancer ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX )
17 Dec 2015
TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy
Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX
TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX )
17 Dec 2015
Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study
Dr Javier Cortes - Vall d´Hebron Institute of Oncology, Barcelona, Spain
Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study ( Dr Javier Cortes - Vall d´Hebron Institute of Oncology, Barcelona, Spain )
17 Dec 2015
ER and FGFR1 interaction critical in endocrine resistant breast cancer
Dr Luigi Formisano - Vanderbilt University Nashville, USA
ER and FGFR1 interaction critical in endocrine resistant breast cancer ( Dr Luigi Formisano - Vanderbilt University Nashville, USA )
16 Dec 2015
Interrupting breast cancer treatment for young women who desire pregnancy
Dr Olivia Pagani and Dr Ann Partridge
Interrupting breast cancer treatment for young women who desire pregnancy ( Dr Olivia Pagani and Dr Ann Partridge )
16 Dec 2015
Treatment outcomes in patients with invasive breast cancer treated with neoadjuv...
Prof Jennifer De Los Santos - University of Alabama, Birmingham, USA
Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging ( Prof Jennifer De Los Santos - University of Alabama, Birmingham, USA )
15 Dec 2015
Novel estrogen receptor-targeting agent represents ‘quantum leap’
Dr Ganesh Raj - UT Southwestern Medical Center, Dallas, USA
Novel estrogen receptor-targeting agent represents ‘quantum leap’ ( Dr Ganesh Raj - UT Southwestern Medical Center, Dallas, USA )
15 Dec 2015
Ductal carcinoma in situ: Anastrozole versus tamoxifen
Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA
Ductal carcinoma in situ: Anastrozole versus tamoxifen ( Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA )
15 Dec 2015
Update on management of the axilla
Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA
Update on management of the axilla ( Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA )
14 Dec 2015
Higher local recurrence after skin-sparing than simple mastectomy for DCIS
Prof Nigel Bundred, University of Manchester, Manchester, United Kingdom
Higher local recurrence after skin-sparing than simple mastectomy for DCIS ( Prof Nigel Bundred, University of Manchester, Manchester, United Kingdom )
14 Dec 2015
Peri-operative lapatinib has profound antiproliferative effect in early breast c...
Prof Nigel Bundred - University of Manchester, Manchester, United Kingdom
Peri-operative lapatinib has profound antiproliferative effect in early breast cancer ( Prof Nigel Bundred - University of Manchester, Manchester, United Kingdom )
14 Dec 2015
Guidelines and management of advanced breast cancer in limited resource settings
Prof Nagi S. El Saghir - American University of Beirut, Beirut, Lebanon
Guidelines and management of advanced breast cancer in limited resource settings ( Prof Nagi S. El Saghir - American University of Beirut, Beirut, Lebanon )
14 Dec 2015
New developments and technologies in hereditary cancer
Dr Johnathan Lancaster - Chief Medical Officer of Myriad Genetics, Salt Lake Cit...
New developments and technologies in hereditary cancer ( Dr Johnathan Lancaster - Chief Medical Officer of Myriad Genetics, Salt Lake City, USA )
14 Dec 2015
Results of the CREATE-X trial
Dr Masakazu Toi - Kyoto University, Kyoto, Japan
Results of the CREATE-X trial ( Dr Masakazu Toi - Kyoto University, Kyoto, Japan )
14 Dec 2015
Hormonal treatments produce similar quality of life outcomes in DCIS
Prof Patricia Ganz - UCLA, Los Angeles, USA
Hormonal treatments produce similar quality of life outcomes in DCIS ( Prof Patricia Ganz - UCLA, Los Angeles, USA )
11 Dec 2015
No significant difference in recurrence rates among women with DCIS taking anast...
Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United King...
No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen ( Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United Kingdom )
11 Dec 2015
Treating women with endocrine-resistant HR /HER2 advanced breast cancer
Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes...
Treating women with endocrine-resistant HR /HER2 advanced breast cancer ( Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes, France. )
11 Dec 2015
No significant difference in recurrence rates among women with DCIS taking anast...
Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United King...
No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen ( Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United Kingdom )
11 Dec 2015
Patients with DCIS receiving anastrozole reported symptoms different from those ...
Prof Patricia Ganz - UCLA, Los Angeles, USA
Patients with DCIS receiving anastrozole reported symptoms different from those receiving tamoxifen both groups reported similar quality of life ( Prof Patricia Ganz - UCLA, Los Angeles, USA )
11 Dec 2015
Estrogen receptor mutations detected in plasma associated with worse overall sur...
Dr Sarat Chandarlapaty - Memorial Sloan Kettering Cancer Center, New York, USA
Estrogen receptor mutations detected in plasma associated with worse overall survival in metastatic breast cancer ( Dr Sarat Chandarlapaty - Memorial Sloan Kettering Cancer Center, New York, USA )
11 Dec 2015
Improved survival outcomes in women with HER2-negative breast cancer after neoad...
Dr Masakazu Toi - Kyoto university, Kyoto, Japan
Improved survival outcomes in women with HER2-negative breast cancer after neoadjuvant chemotherapy ( Dr Masakazu Toi - Kyoto university, Kyoto, Japan )
10 Dec 2015
Breast-conserving therapy yields better 10-year outcomes than mastectomy for ear...
Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Net...
Breast-conserving therapy yields better 10-year outcomes than mastectomy for early-stage patients ( Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands )
10 Dec 2015
Adding carboplatin to presurgery chemotherapy improved disease-free survival for...
Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany
Adding carboplatin to presurgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer ( Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany )
10 Dec 2015
Mastectomy plus reconstruction has higher complication rates and costs than lump...
Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center, Hous...
Mastectomy plus reconstruction has higher complication rates and costs than lumpectomy plus radiation ( Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center, Houston, USA )
10 Dec 2015
Analysis of blood samples finds ESR1 gene mutations are prevalent and associated...
Dr Sarat Chanderlapaty - Memorial Sloan Kettering Cancer Center, New York, USA
Analysis of blood samples finds ESR1 gene mutations are prevalent and associated with worse overall survival ( Dr Sarat Chanderlapaty - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Dec 2015
Breast-conserving therapy yielded better outcomes than mastectomy for early-stag...
Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Net...
Breast-conserving therapy yielded better outcomes than mastectomy for early-stage patients ( Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands )
10 Dec 2015
Mastectomy plus reconstruction has higher complication rates and costs than lump...
Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center, Hous...
Mastectomy plus reconstruction has higher complication rates and costs than lumpectomy plus radiation ( Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center, Houston, USA )
10 Dec 2015
Resistance of ER-positive breast cancer to tamoxifen therapy may be driven by AP...
Dr Reuben Harris - Howard Hughes Medical Institute, Minneapolis, USA
Resistance of ER-positive breast cancer to tamoxifen therapy may be driven by APOBEC3B ( Dr Reuben Harris - Howard Hughes Medical Institute, Minneapolis, USA )
10 Dec 2015
Denosumab improves disease-free survival for postmenopausal patients with HR-pos...
Prof Michael Gnant - Medical University of Vienna, Vienna, Austria
Denosumab improves disease-free survival for postmenopausal patients with HR-positive breast cancer ( Prof Michael Gnant - Medical University of Vienna, Vienna, Austria )
9 Dec 2015
Test to identity which breast cancer patients will respond to platinum-based che...
Dr Johnathan Lancaster - Chief Medical Officer of Myriad Genetics, Salt Lake Cit...
Test to identity which breast cancer patients will respond to platinum-based chemotherapy ( Dr Johnathan Lancaster - Chief Medical Officer of Myriad Genetics, Salt Lake City, USA )
9 Dec 2015
Overexpression of the enzyme APOBEC3B is linked to somatic mutagenesis in breast...
Dr Reuben Harris - Howard Hughes Medical Institute, Chevy Chase, USA
Overexpression of the enzyme APOBEC3B is linked to somatic mutagenesis in breast and other cancers ( Dr Reuben Harris - Howard Hughes Medical Institute, Chevy Chase, USA )
9 Dec 2015
Women with luminal A breast cancer subtype do not seem to benefit from adjuvant ...
Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada
Women with luminal A breast cancer subtype do not seem to benefit from adjuvant chemotherapy ( Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada )
9 Dec 2015
Denosumab improves disease-free survival for postmenopausal HR-positive breast c...
Prof Michael Gnant - Medical University of Vienna, Vienna, Austria
Denosumab improves disease-free survival for postmenopausal HR-positive breast cancer ( Prof Michael Gnant - Medical University of Vienna, Vienna, Austria )
9 Dec 2015
Women with luminal A subtype of breast cancer did not benefit from adjuvant chem...
Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada
Women with luminal A subtype of breast cancer did not benefit from adjuvant chemotherapy ( Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada )
9 Dec 2015
Pathologic complete response to presurgery chemo improves survival for triple-ne...
Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA
Pathologic complete response to presurgery chemo improves survival for triple-negative breast cancer ( Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA )
9 Dec 2015